Danaher reports Q1 2026 net earnings of $1B, raises full-year EPS guidance amid steady revenue growth.

Danaher Corporation announced Q1 2026 net earnings of $1.0 billion, or $1.45 per diluted share, with adjusted EPS up 9.5% to $2.06. Revenues rose 3.5% year-over-year to $6.0 billion, driven by strong Bioprocessing and Life Sciences segments despite a weaker respiratory season. The company plans to acquire Masimo Corporation to expand its patient monitoring portfolio and raised its full-year adjusted EPS guidance to $8.35-$8.55. Danaher expects continued core revenue growth and strong cash flow to support further investments and acquisitions.